GSK plans to divest old drugs except in emerging markets
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has plans to divest its older drugs in European and US regions, but it is in no rush to strike a deal and nor does it think any mega transactions will take place for its established products portfolio, a source familiar with the matter told Scrip.